Swedish Orphan Biovitrum Reports Q3 Revenue Growth and Upgrades FY2026 Outlook
Swedish Orphan Biovitrum AB (BIOVF) reported strong third-quarter financial results, highlighted by a 17.2% year-over-year increase in revenue to SEK 9.12 billion. The company achieved a Non-GAAP earnings per share (EPS) of SEK 6.96 and maintained stable operating cash flow at SEK 1,871 million. Following these results, the company has upgraded its full-year 2026 revenue guidance. Management now anticipates revenue growth in the high-teens to low-20s percentage range at constant exchange rates (CER), an increase from the previously projected mid-to-high-teens. The adjusted EBITA margin outlook remains steady, expected to fall within the mid-to-high 30% range.
Tickers: $SWOBY
Topics: earnings report financial guidance profitability revenue growth
Read the full article at Seeking Alpha
Part of the story Swedish Orphan Biovitrum Reports Q3 Revenue Growth and Upgrades FY2026 Outlook (6 articles)